The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Hims & Hers Health (NYSE:HIMS) shares were on a massive run, but that momentum hit a wall recently. Since its peak on ...

As it gets harder to offer compounded GLP-1s, many telehealth companies are pivoting to hormone replacement therapy.

Hims & Hers Health ( HIMS -12.79%) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some ...

Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...

FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

Hims & Hers hinted that the company’s providers ... if they’ve been taking a compounded copy of a [GLP-1] drug, that era is coming to an end.” It’s a hard reality for patients to accept.

Hims & Hers Health stock drops over 20% after the FDA removes semaglutide from the shortage list. Novo Nordisk launches a ...

many of whom get the medication from telehealth providers such as Hims & Hers, Ro, Mochi and Eden. Tirzepatide is approved by the Food and Drug Administration (FDA) for treating type 2 diabetes and ...